Monoclonal and polyclonal antibodies as biomarkers to measure oxidative stress to diagnose and manage diseases associated with chronic inflammation.
- Measures irreversible protein oxidative damage in order to quantify oxidative stress observed in cancer, diabetes, psychiatric disorders, and other diseases.
- Shows as high as a 20-fold difference between healthy individuals and coronary artery and renal disease patients.
- Displays high sensitivity to oxidative damage - biomarkers can be detected at picomolar levels.
- Specific detection of damaged low-density lipoproteins (LDL) can be documented.
Oxidative stress and chronic inflammation are central to the pathogenesis of a wide variety of diseases including but not limited to coronary artery disease, neurodegenerative diseases, renal diseases, rheumatoid arthritis, diabetes, and cancer. Today, most biomarkers developed for oxidative stress are used to measure the effects of smoking and assess lung diseases. There are currently no fully validated markers of oxidative stress for these diseases characterized by chronic inflammation. Such biomarkers could be used to diagnose and manage these diseases in millions of patients.
Emory investigators have designed a set of immunoassay methods to detect and quantify biomarkers of oxidative stress in proteins, specifically low-density lipoproteins (LDL). In principle, the novel biomarker may be any amino acid that has undergone oxidation but emphasis is given to oxidized sulfur- or selenium-containing amino acids due to their susceptibility to oxidation. The biomarker is detected using polyclonal and monoclonal antibodies bound to a solid phase support that are specific to any sulfur- or selenium-containing protein, peptide or proteinaceous aggregate. The oxidatively damaged proteins can be isolated from a biological sample, therefore allowing the rate of production and removal of these damaged proteins to be determined in vivo. These biomarkers have very versatile applications, including diagnosis, treatment, and management of early stages of diseases associated with inflammation and/or oxidative stress. In addition, they can be used to assess the effectiveness of various antioxidant interventions and large population-based molecular epidemiologic studies.
A prototype diagnostic kit has been prepared, tested, and validated using human biological samples.